An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. [electronic resource]
Producer: 20140728Description: 457-68 p. digitalISSN:- 1476-4679
- Animals
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Clinical Trials, Phase II as Topic
- Drug Resistance, Neoplasm -- genetics
- ErbB Receptors -- antagonists & inhibitors
- Erlotinib Hydrochloride
- Female
- Humans
- Integrin alphaVbeta3 -- metabolism
- Integrin beta3 -- genetics
- Lung Neoplasms -- drug therapy
- Mice
- Mice, Inbred NOD
- Mice, Nude
- Mice, SCID
- Molecular Targeted Therapy
- Neoplastic Stem Cells -- drug effects
- Phenotype
- Protein Kinase Inhibitors -- therapeutic use
- Protein Serine-Threonine Kinases -- antagonists & inhibitors
- Proto-Oncogene Proteins -- genetics
- Proto-Oncogene Proteins c-rel -- antagonists & inhibitors
- Proto-Oncogene Proteins p21(ras)
- Quinazolines -- therapeutic use
- RNA Interference
- Randomized Controlled Trials as Topic
- Signal Transduction -- drug effects
- Spheroids, Cellular
- Time Factors
- Transfection
- Tumor Burden -- drug effects
- Tumor Cells, Cultured
- Xenograft Model Antitumor Assays
- ral GTP-Binding Proteins -- genetics
- ras Proteins -- genetics
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.